Sabatolimab

DB16322InvestigationalProtein Based Therapies

Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).

Mechanism: Pharmacologically active on Hepatitis A virus cellular receptor 2
Curator reviewed
Also known as: Anti-tim-3 monoclonal antibody mbg453 · Anti-tim3 checkpoint inhibitor mbg453 · Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer · Immunoglobulin g4-kappa, anti-(homo sapiens havcr2 (hepatitis a virus cellular receptor 2, t-cell immunoglobulin mucin family member 3, tim-3, tim3, timd3, cd366)), humanized monoclonal antibody
Code names: MBG-453

Resolves to

Compound

UNII3L7R886Y06CAS2252262-24-9

Clinical / RWD

ATCL01FX19

Targets

Q8TDQ0HAVCR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 11 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sabatolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account